S.O.L.A.R.I.S. A New Dawn in Next-generation Car-t Manufacturing
- Coordinator
- Miltenyi Biotec BV & Co Kg, Germany
- Runs
- 1 July 2026 to 30 June 2030
- Status
- Running
- EU funding
- €8.0m
- Total cost
- —
- Partners
- 14 organisations in 8 countries
- Type
- Innovation Action
- Grant agreement
- 101286693
What the project is doing
In the project's own words, from its summary on CORDIS.
Advanced Therapy Medicinal Products (ATMPs), such as CAR T cell therapies, offer transformative clinical benefits for patients with otherwise untreatable diseases. However, their potential remains severely limited by complex, costly, and difficult-to-scale manufacturing processes, as well as prolonged vein-to-vein times that often exceed several weeks. The proposed project S.O.L.A.R.I.S addresses these critical challenges by further developing and enhancing the functionality of a clinically proven and widely-adopted integrated manufacturing solution for CAR T cells: the CliniMACS (CM) Prodigy Platform.
SOLARIS will design, integrate, and validate several innovative modules that transform the CM Prodigy into a digitally enhanced, end-to-end automated, GMP-compatible and aseptically closed manufacturing solution. These modules will be plug-and-play compatible with existing CM Prodigies worldwide, enabling rapid adoption across diverse healthcare and manufacturing environments. Validation will be conducted at six EU ATMP manufacturing hubs, strategically selected to cover a wide range of infrastructures: from established clinical and industrial sites to a newly built facility.
This approach will provide a proof-of-concept for accelerated technology transfer, improved process consistency, reduced regulatory and technical risks, and significant gains in cost- and time-efficiency as well as scalability. The consortium integrates technical, clinical, regulatory, and sustainability expertise, ensuring a rapid route to clinical adoption. By advancing the manufacturing capabilities of the hubs, SOLARIS will generate best-practice examples for future EU Centres-of-Excellence, aligned with initiatives such as the European University Hospital Alliance and JOIN4ATMP.
SOLARIS will demonstrate how optimized manufacturing can enhance equitable patient access to ATMPs across Europe, strengthen EU competitiveness in advanced therapies, and contribute to resilient healthcare systems.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Miltenyi Biotec BV & Co Kg | Bergisch Gladbach | Germany | Coordinator |
| Interuniversitair Micro-Electronica Centrum | Leuven | Belgium | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Green Elephant Biotech GmbH | Giessen | Germany | Participant |
| future8 gGmbH | St. Ingbert | Germany | Participant |
| 2.-0 Lca Consultants Aps | Aalborg | Denmark | Participant |
| Icosagen Cell Factory Ou | Kambja Vald | Estonia | Participant |
| Fundacio Privada per a La Recerca I La Docencia Sant Joan De Deu | Esplugues De Llobregat | Spain | Participant |
| Hospital Sant Joan De Deu | Esplugues De Llobregat | Spain | Third party |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Stichting IMEC Nederland | Eindhoven | Netherlands | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Autolus Limited | London | United Kingdom | Participant |
| Cell Therapy Catapult Limited | London | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI